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Voxelotor (Oxbryta, Global Blood Therapeutics (GBT) 440) 
was developed by GBT for the treatment of sickle cell disease 
(SCD) in adults and children 12 years of age and older. It ex-
erts its action by binding to the amino acid terminal of both α 
chains of hemoglobin (Hb). This, in turn, prevents or decreases 
the polymerization of hemoglobin S (HbS) by increasing Hb 
oxygen affinity. The efficacy and safety of voxelotor in SCD 
was evaluated in a phase III randomized, double-blind, place-
bo-controlled multicenter trial in combination with and with-
out Hounsfield unit (HU) (Heart Outcome Prevention Evalu-
ation Trial (HOPE Trial)) [1]. It was approved by the United 
States Food and Drug Administration on November 19, 2019 
[2]. The approval was accelerated based on increase in Hb. 
Continued approval for this indication may be contingent upon 
verification and description of clinical benefit in confirmatory 
trial(s).
Efficacy was based on Hb response rate defined as Hb in-
crease of > 1 g/dL from baseline to week 24 in patients treated 
with voxelotor 1,500 mg versus placebo. The response rate 
for voxelotor 1,500 mg was 51.1% (46/90) compared to 6.5% 
(6/92) in the placebo group (P < 0.001).
Recommended dosage of voxelotor is 1,500 mg orally 
once daily with or without food. Recommended dosage for se-
vere hepatic impairment is 1,000 mg orally once daily with or 
without food [2].
From the pharmacokinetic point of view, in vitro and in 
vivo studies showed that voxelotor is excessively metabolized 
through phase I metabolism that includes the utilization of cy-
tochrome P450 (CYP450) enzymes (oxidation and reduction), 
phase II (glucuronidation) and a combination of both phases. 
Oxidation of voxelotor is mediated mostly by CYP3A4 en-
zyme with minor contributions from CYP2CI9, CYP2B6 and 
CYP2C9 [2]. This multiplicity of metabolic pathways renders 
voxelotor vulnerable to drug-drug interactions where other 
dugs affect its metabolism or, conversely, where voxelotor 
itself affects the metabolism of other drugs. Thus, the daily 
dose of voxelotor has to be adjusted in the presence of strong 
CYP3A4 inhibitors, to 1,000 mg once daily because inhibi-
tion of CYP3A4 maintains a relatively higher concentration of 
voxelotor in the blood. Conversely, inducers of CYP3A4 result 
in rapid degradation of voxelotor into inactive metabolites that 
require increasing the dose to 2,500 mg once daily [2]. Potent 
inducers of CYP3A4 that may be prescribed to patients with 
SCD include barbiturates, carbamazepine, phenytoin, dexa-
methasone and rifampin. Potent inhibitors of CYP3A4 often 
prescribed to patients with SCD include cimetidine, fluoroqui-
nolones, selective serotonin reuptake inhibitors, quinine, mac-
rolides and calcium-channel blockers (diltiazem).
The plot thickens if the metabolic profile of opioids is 
brought into the picture. The significance of the role of opi-
oids to manage the pain of the acute painful vaso-occlusive 
crisis (VOCs) becomes evident from the recent advances in 
understanding the pharmacogenomics of drugs in general in-
cluding the opioids [3]. The metabolism of certain opioids also 
includes phase I pathway shown in Table 1. Phase I involves 
the CYP450 enzymes whereas glucuronidation is the major 
metabolic pathway in phase II metabolism. Phase I metabo-
lism of opioids involves primarily the CYP3A4 and CYP2D6 
enzymes. The CYP3A4 enzyme metabolizes more than 50% 
of all drugs; consequently, opioids metabolized by this enzyme 
have a high risk of drug-drug interactions [4]. The CYP2D6 
enzyme metabolizes fewer drugs and is therefore associated 
with an intermediate risk of drug-drug interactions [4]. The 
CYP3A4 enzyme is the primary metabolizer of fentanyl and 
oxycodone, although normally some oxycodone undergoes 
CYP2D6-mediated metabolism to oxymorphone (Table 1) [4]. 
Tramadol undergoes both CYP3A4-mediated and CYP2D6-
mediated metabolism. Methadone is primarily metabolized by 
CYP3A4 and CYP2B6. CYP2C8, CYP2CD19, CYP2D6, and 
CYP2C9 also contribute in variable degrees to its metabolism 
[5]. Since voxelotor itself inhibits CYP3A4, the co-adminis-
tration of certain opioids (hydrocodone, oxycodone, fentanyl 
and methadone) shown in Table 1 will increase their analgesic 
effect and/or their side effects especially after multiple dos-
ing. Figure 1 shows an example of the effect of inhibiting the 
CYP3A4 enzyme on the analgesic efficacy of fentanyl. The 
same applies to oxycodone, methadone and tramadol.
The plot thickens further considering the complexity of 
the pharmacogenomics of the CYP450 system where the en-
zymes may be deleted, mutated, duplicated or even triplicated 
[6]. Human CYP consists of 21 currently described families 
and 20 subfamilies coded by 57 genes and 58 pseudogenes [7]. 
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The CYP isoforms 1, 2, and 3 are responsible for the majority 
of hepatic drug metabolism. Of these, CYP2C9 and CYP2D6 
are involved in the metabolism of several drugs used for pain 
control including opioid and nonopioid analgesics. Phase I me-
tabolism of opioids involves primarily the CYP3A4 and CY-
P2D6 enzymes. The CYP3A4 enzyme metabolizes more than 
50% of all drugs; consequently, opioids metabolized by this 
enzyme have a high risk of drug-drug interactions. Accord-
ingly, medications used in addition to opioids may enhance or 
inhibit the metabolism of the opioid in question.
In the phase III trial of voxelotor [1], a VOC during treat-
ment was defined, among other things, as pain that required 
treatment with oral or parental opioids, ketorolac, or other 
analgesics. Usually opioids are used routinely in most cas-
es. However, the specific opioids used were not mentioned. 
Thus, we do not know if the opioids used belonged to phase I 
CYP450 or to phase II glucuronidation. This might have cre-
ated a confounding factor.
Thus, if the voxelotor group received more opioids me-
tabolized by CYP3A4 shown in Table 1, the chances are that 
they may have achieved better pain control than the placebo 
group and hence, requiring less intake of more opioids. The 
voxelotor (HOPE) trial did not mention the amount of opioid 
intake by the groups involved in the study.
If the voxelotor group did indeed consume fewer opioids, 
this would have been considered a positive clinical response. 
Future trials should consider the specific opioids used espe-
cially if the drug being studied inhibits certain CYP450 en-
zymes shown in Table 1. It is highly recommended that future 
such studies limit the use of opioids to opioids phase II drugs 
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Table 1.  Metabolism of Certain Opioids Used in Sickle Cell Disease by the Cytochrome P450 Enzymes
Opioid CYP450 enzyme Active metabolite
Codeine CYP2D6 Morphine, hydrocodone
Hydrocodone CYP2D6, 3A4 Hydromorphone
Oxycodone CYP2D6, 3A4 Oxymorphone
Fentanyl CYP3A4 None
Methadone CYP2D6, 3A4, 2C8, 2C9, 2C19, 2B6, 1A2 None
Tramadol CYP2D6, 3A4, 2B6 None
Adapted from Ballas S. K. Sickle Cell Pain, Second Edition. Washington DC: International Association for the Study of Pain; 2014. CYP450: cyto-
chrome P450.
Figure 1. Effect of CYP3A4 enzyme on the metabolism of fentanyl. Equation A shows how CYP3A4 enzyme usually metabolizes 
fentanyl by oxidizing it to inactive metabolites and hence, decreases its concentration in blood. Equation B shows that inhibition 
of CYP3A4 decreases the oxidation of fentanyl to inactive metabolites and hence, maintains its concentration in blood to maintain 
or increase its analgesic effect.
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